Vaccine shown to be 95% effective in final efficacy analysis of Phase 3 trial
- Plans to file for emergency-use authorisation within days
- No serious safety concerns observed in the tiral
- Side effects were mostly mild to moderate, cleared up quickly
- Only significant side effect greater than 2% frequency was fatigue at 3.7%
Risk trades are getting another shot in the arm on the news here, albeit a more modest one this time around. European stocks are holding slight gains now of around 0.4% while US futures are pushing slightly higher as well on the headlines.
The 95% efficacy rate bugs me a little, as this sort of reflects that this has turned into a huge vaccine race after Moderna announced a 94.5% efficacy rate earlier this week.
But if they have the data to back that up, then sure all the better for humanity.
Based on the graph above I found that on the top of the list we got Oats and VIX today and on the bottom Silver and Platinum.
Gold is negative on the list today, which is another sign of the weakness..
Key Levels:
Resistance: $1,9000
Support levels: $1,850 and $1,820.
